Literature DB >> 8522429

Emergency primary coronary angioplasty in patients with acute myocardial infarction who are unsuitable for intravenous thrombolysis.

C J McKenna1, M Codd, H A McCann, D D Sugrue.   

Abstract

Intravenous thrombolytic therapy is now accepted as the standard method of achieving coronary reperfusion in patients with acute myocardial infarction. There are several important limitations. Primary percutaneous transluminal coronary angioplasty is an attractive method for reopening occluded coronary arteries. Between 1986 and 1993, 14 patients in whom there was an absolute contraindication to thrombolysis underwent emergency coronary angioplasty as the primary treatment for acute myocardial infarction. Coronary artery patency was restored in 13/14 (93%). One patient died in hospital. The median follow-up was one year. One patient suffered a further myocardial infarction and one patient required coronary artery bypass surgery at follow-up. Emergency coronary angioplasty services should be developed to treat those patients in whom there is a contraindication to thromboloysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8522429     DOI: 10.1007/bf02967203

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  40 in total

1.  What proportion of patients with myocardial infarction are suitable for thrombolysis?

Authors:  N Murray; J Lyons; C Layton; R Balcon
Journal:  Br Heart J       Date:  1987-02

2.  Adoption of thrombolytic therapy in the management of acute myocardial infarction.

Authors:  M A Hlatky; H Cotugno; C O'Connor; D B Mark; D B Pryor; R M Califf
Journal:  Am J Cardiol       Date:  1988-03-01       Impact factor: 2.778

3.  Primary angioplasty for acute myocardial infarction in 1,000 consecutive patients. Results in an unselected population and high-risk subgroups.

Authors:  J H O'Keefe; W L Bailey; B D Rutherford; G O Hartzler
Journal:  Am J Cardiol       Date:  1993-12-16       Impact factor: 2.778

4.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

5.  Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups.

Authors:  R J Gibbons; D R Holmes; G S Reeder; K R Bailey; M R Hopfenspirger; B J Gersh
Journal:  N Engl J Med       Date:  1993-03-11       Impact factor: 91.245

6.  Limitation of infarct size and preservation of left ventricular function after primary coronary angioplasty compared with intravenous streptokinase in acute myocardial infarction.

Authors:  M J de Boer; H Suryapranata; J C Hoorntje; S Reiffers; A L Liem; K Miedema; W T Hermens; M J van den Brand; F Zijlstra
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

7.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.

Authors:  E J Topol; R M Califf; B S George; D J Kereiakes; C W Abbottsmith; R J Candela; K L Lee; B Pitt; R S Stack; W W O'Neill
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

8.  Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. AIMS Trial Study Group.

Authors: 
Journal:  Lancet       Date:  1988-03-12       Impact factor: 79.321

9.  A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days.

Authors: 
Journal:  N Engl J Med       Date:  1986-06-05       Impact factor: 91.245

10.  Candidates for thrombolysis among emergency room patients with acute chest pain. Potential true- and false-positive rates.

Authors:  T H Lee; M C Weisberg; D A Brand; G W Rouan; L Goldman
Journal:  Ann Intern Med       Date:  1989-06-15       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.